drugset
drugset / Trial / NCT05071313

A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older

NCT05071313 ↗

Phase 3 Completed 777 enrolled Janssen Vaccines & Prevention B.V.
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to evaluate the immunogenicity and safety of Ad26.RSV.preF-based vaccine and quadrivalent high-dose seasonal influenza vaccine when administered either concomitantly or separately.

Timeline

Start
2021-10-04
Primary completion
2022-04-20
Completion
2022-10-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Ad26.RSV.preF-based vaccine Vaccine — Intramuscular
Subject Quadrivalent High-dose Influenza Vaccine Vaccine — Intramuscular

Indications

respiratory syncytial virus infectious disease